Form 4: Seres Director Sells Shares for Tax Coverage

Seres Therapeutics Director Eric D. Shaff reported the acquisition of common stock through RSU vesting and subsequent sale of shares to cover tax obligations under a pre-arranged 10b5-1 plan.

Summary

• Director Eric D. Shaff acquired 391 shares and 333 shares of Seres Therapeutics common stock on August 15, 2025, through the vesting of Restricted Stock Units (RSUs).
• On August 18, 2025, Mr. Shaff sold 217 shares of common stock at a price of $16.65 per share.
• The sale was executed under a Rule 10b5-1 plan adopted on March 2, 2023, specifically to cover tax liabilities associated with the RSU vesting.
• Following these transactions, Mr. Shaff beneficially owns 10,609 shares of Seres Therapeutics common stock directly.
• Two tranches of RSUs had initial vesting dates of February 15, 2024, and February 15, 2025, respectively, with remaining units vesting in 12 equal quarterly installments.

Sentiment

Score: 7

Explanation: The transaction is a routine tax-related sale of shares acquired through RSU vesting, executed under a pre-arranged 10b5-1 plan, which is generally viewed as a neutral event rather than a signal of management's view on the company's prospects.

Positives

• The sale was pre-planned under a Rule 10b5-1 plan, indicating it was not a discretionary sale based on a negative outlook.
• The sale was explicitly for tax coverage, not a general disposition of shares, which is a routine and expected event for insider compensation.

Negatives

• A director selling shares, even for tax purposes, results in a reduction of their direct ownership stake in the company.

Future Outlook

NA

Management Comments

• The sales reported were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.

Industry Context

This Form 4 filing details a routine insider transaction specific to Seres Therapeutics, Inc. and does not provide information relevant to broader industry trends or competitive dynamics.

Stakeholder Impact

• Shareholders: The sale represents a minor reduction in a director's direct ownership, but given it's for tax purposes under a pre-planned arrangement, the impact on shareholder sentiment is likely minimal.
• Employees: No direct impact on employees is indicated by this filing.

Next Steps

• Remaining restricted stock units will vest and settle in 12 equal quarterly installments.

Key Dates

Recommendation

The reported transactions are routine insider sales for tax purposes following RSU vesting, executed under a pre-arranged 10b5-1 plan. This type of transaction does not typically indicate a change in the company's fundamental outlook or warrant a change in investment recommendation. Therefore, a 'hold' recommendation is maintained, pending further operational or financial updates from the company.

Keywords

Seres Therapeutics, MCRB, Form 4, Insider Transaction, Stock Sale, RSU, Restricted Stock Units, 10b5-1 Plan, Director, Eric D. Shaff